{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:47:48Z","timestamp":1792813668284,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007637","name":"German University in Cairo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007637","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Antibiotic resistance is a cause of serious illness and death, originating often from insufficient permeability into gram-negative bacteria. Nanoparticles (NP) can increase antibiotic delivery in bacterial cells, however, may as well increase internalization in mammalian cells and toxicity. In this work, NP in liposome (NP-Lip) formulations were used to enhance the selectivity of the antibiotics (3C and tobramycin) and quorum sensing inhibitor (HIPS-1635) towards <jats:italic>Pseudomonas aeruginosa<\/jats:italic> by fusing with bacterial outer membranes and reducing uptake in mammalian cells due to their larger size. Poly (lactic-co-glycolic) acid NPs were prepared using emulsion solvent evaporation and incorporated in larger liposomes. Cytotoxicity and uptake studies were conducted on two lung cell lines, Calu-3 and H460. NP-Lip showed lower toxicity and uptake in both cell lines. Then formulations were investigated for suitability for oral inhalation. The deposition of NP and NP-Lip in the lungs was assessed by next generation impactor and corresponded to 75% and 45% deposition in the terminal bronchi and the alveoli respectively. Colloidal stability and mucus-interaction studies were conducted. NP-Lip showed higher diffusion through mucus compared to NPs with the use of nanoparticle tracking analyzer. Moreover, the permeation of delivery systems across a liquid-liquid interface epithelial barrier model of Calu-3 cells indicated that NP-Lip could cause less systemic toxicity upon in-vivo like administration by aerosol deposition. Monoculture and <jats:italic>Pseudomonas aeruginosa<\/jats:italic> biofilm with Calu-3 cells co-culture experiments were conducted, NP-Lip achieved highest toxicity towards bacterial biofilms and least toxicity % of the Calu-3 cells. Therefore, the NP- liposomal platform offers a promising approach for enhancing antibiotic selectivity and treating pulmonary infections.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1007\/s13346-024-01662-2","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T16:01:54Z","timestamp":1721836914000},"page":"1193-1209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nanoparticles in liposomes: a platform for increased antibiotic selectivity in multidrug resistant bacteria in respiratory tract infections"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5423-6937","authenticated-orcid":false,"given":"Nathalie E.","family":"Fakhoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abdel-Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa M.","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Empting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Boese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitta","family":"Loretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus-Michael","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma N.","family":"Tammam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"2","key":"1662_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/J.IDC.2016.02.004","volume":"30","author":"D van Duin","year":"2016","unstructured":"van Duin D, Paterson DL. Multidrug-resistant Bacteria in the community: trends and lessons learned. Infect Dis Clin N Am. Jun. 2016;30(2):377\u201390. https:\/\/doi.org\/10.1016\/J.IDC.2016.02.004.","journal-title":"Infect Dis Clin N Am"},{"issue":"1","key":"1662_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","volume":"37","author":"Z Pang","year":"2019","unstructured":"Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37(1):177\u201392. https:\/\/doi.org\/10.1016\/j.biotechadv.2018.11.013.","journal-title":"Biotechnol Adv"},{"key":"1662_CR3","doi-asserted-by":"publisher","unstructured":"Masi M, R\u00e9fregiers M, Pos KM, Pag\u00e8s JM. Mechanisms of envelope permeability and antibiotic influx and efflux in gram-negative bacteria. Nat Microbiol. 2017;2(3) https:\/\/doi.org\/10.1038\/nmicrobiol.2017.1.","DOI":"10.1038\/nmicrobiol.2017.1"},{"issue":"3","key":"1662_CR4","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3934\/microbiol.2018.3.482","volume":"4","author":"WC Reygaert","year":"2018","unstructured":"Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018;4(3):482\u2013501. https:\/\/doi.org\/10.3934\/microbiol.2018.3.482.","journal-title":"AIMS Microbiol"},{"issue":"3","key":"1662_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s12016-008-8079-9","volume":"35","author":"VE Wagner","year":"2008","unstructured":"Wagner VE, Iglewski BH. P. Aeruginosa biofilms in CF infection. Clin Rev Allergy Immunol. 2008;35(3):124\u201334. https:\/\/doi.org\/10.1007\/s12016-008-8079-9.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"8","key":"1662_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s1357-4310(00)01739-1","volume":"6","author":"Y Tan","year":"2000","unstructured":"Tan Y, Tillett DJ, Mckay IA, Tan Y. Molecular strategies for overcoming antibiotic resistance in bacteria. Mol Med Today. 2000;6(8):309\u201314. https:\/\/doi.org\/10.1016\/s1357-4310(00)01739-1.","journal-title":"Mol Med Today"},{"issue":"36","key":"1662_CR7","doi-asserted-by":"publisher","first-page":"12606","DOI":"10.1002\/chem.201601315","volume":"22","author":"V Ng","year":"2016","unstructured":"Ng V, Chan WC. New found Hope for antibiotic discovery\u00a0: lipid II inhibitors. Chemistry (Easton). 2016;22(36):12606\u201316. https:\/\/doi.org\/10.1002\/chem.201601315.","journal-title":"Chemistry (Easton)"},{"issue":"4\u20135","key":"1662_CR8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.addr.2009.11.024","volume":"62","author":"NS Santos-Magalh\u00e3es","year":"2010","unstructured":"Santos-Magalh\u00e3es NS, Mosqueira VCF. Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev. 2010;62(4\u20135):560\u201375. https:\/\/doi.org\/10.1016\/j.addr.2009.11.024.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"1662_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","volume":"83","author":"L Zhang","year":"2008","unstructured":"Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761\u20139. https:\/\/doi.org\/10.1038\/sj.clpt.6100400.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1662_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2174\/092986710790416290","volume":"17","author":"L Zhang","year":"2010","unstructured":"Zhang L, Pornpattananangkul D, Hu C-M, Huang C-M. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem. 2010;17(6):585\u201394. https:\/\/doi.org\/10.2174\/092986710790416290.","journal-title":"Curr Med Chem"},{"issue":"9","key":"1662_CR11","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1021\/acs.molpharmaceut.2c00258","volume":"19","author":"S Fangary","year":"2022","unstructured":"Fangary S, et al. Nanoparticle fraught liposomes: a platform for increased antibiotic selectivity in multidrug resistant Bacteria. Mol Pharm. 2022;19(9):3163\u201377. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00258.","journal-title":"Mol Pharm"},{"key":"1662_CR12","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.2147\/IJN.S55807","volume":"11","author":"Z Wang","year":"2016","unstructured":"Wang Z, et al. Fusion between fluid liposomes and intact bacteria: study of driving parameters and in vitro bactericidal efficacy. Int J Nanomedicine. 2016;11:4025\u201336. https:\/\/doi.org\/10.2147\/IJN.S55807.","journal-title":"Int J Nanomedicine"},{"issue":"43","key":"1662_CR13","doi-asserted-by":"publisher","first-page":"6714","DOI":"10.2174\/1381612823666171122104738","volume":"23","author":"SN Tammam","year":"2017","unstructured":"Tammam SN. Lipid based nanoparticles as inherent reversing agents of multidrug resistance in Cancer. Curr Pharm Des. 2017;23(43):6714\u201329. https:\/\/doi.org\/10.2174\/1381612823666171122104738.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"1662_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/etc.2470","volume":"33","author":"K Kettler","year":"2014","unstructured":"Kettler K, Veltman K, van de Meent D, van Wezel A, Hendriks AJ. Critical review cellular uptake of nanoparticles as determined by particle properties, experimental conditions, and cell type. Environ Toxicol Chem. 2014;33(3):481\u201392. https:\/\/doi.org\/10.1002\/etc.2470.","journal-title":"Environ Toxicol Chem"},{"key":"1662_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13756-019-0533-3","volume":"8","author":"S Divakar","year":"2019","unstructured":"Divakar S, Lama M, Asad KU. Antibiotics versus biofilm: an emerging battleground in microbial communities. Antimicrob Resist Infect Control. 2019;8:76. https:\/\/doi.org\/10.1186\/s13756-019-0533-3.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"1662_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bmcl.2003.09.082","volume":"14","author":"GD Francisco","year":"2004","unstructured":"Francisco GD, et al. Phenyl thiazolyl urea and carbamate derivatives as new inhibitors of bacterial cell-wall biosynthesis. Bioorganic Med Chem Lett. 2004;14(1):235\u20138. https:\/\/doi.org\/10.1016\/j.bmcl.2003.09.082.","journal-title":"Bioorganic Med Chem Lett"},{"key":"1662_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/advs.202204443","volume":"2204443","author":"MM Hamed","year":"2023","unstructured":"Hamed MM, et al. Towards translation of PqsR inverse agonists: from in vitro efficacy optimization to in vivo proof-of-principle. Adv Sci. 2023;2204443:1\u201314. https:\/\/doi.org\/10.1002\/advs.202204443.","journal-title":"Adv Sci"},{"key":"1662_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejpb.2018.11.018","volume":"134","author":"R Hassan","year":"2019","unstructured":"Hassan R, et al. Prevention of hepatic stellate cell activation using JQ1- and atorvastatin- loaded chitosan nanoparticles as a promising approach in therapy of liver fi brosis. Eur J Pharm Biopharm. 2019;134:96\u2013106. https:\/\/doi.org\/10.1016\/j.ejpb.2018.11.018.","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"1662_CR19","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/jac\/dkab068","volume":"76","author":"S Frisch","year":"2021","unstructured":"Frisch S, et al. A pulmonary mucus surrogate for investigating antibiotic permeation and activity against Pseudomonas aeruginosa biofilms. J Antimicrob Chemother. 2021;76(6):1472\u20139. https:\/\/doi.org\/10.1093\/jac\/dkab068.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1662_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-38915-x","volume":"9","author":"A Kim","year":"2019","unstructured":"Kim A, Ng WB, Bernt W, Cho NJ. Validation of size estimation of nanoparticle tracking analysis on Polydisperse macromolecule assembly. Sci Rep. 2019;9(1):1\u201314. https:\/\/doi.org\/10.1038\/s41598-019-38915-x.","journal-title":"Sci Rep"},{"key":"1662_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/entl-2015-0003","volume":"3","author":"C Schulze","year":"2011","unstructured":"Schulze C, Schaefer UF, Voetz M, Wohlleben W, Venzago C. Transport of metal oxide nanoparticles across Calu-3 cell monolayers modelling the air-blood barrier. EURO-NanoTox-Lett. 2011;3:1\u201310.","journal-title":"EURO-NanoTox-Lett"},{"key":"1662_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/smll.202100531","volume":"2100531","author":"CR Thorn","year":"2021","unstructured":"Thorn CR, Carvalho-wodarz CDS, Horstmann JC, Lehr C, Prestidge CA, Thomas N. Tobramycin liquid crystal nanoparticles eradicate cystic fibrosis-related Pseudomonas aeruginosa biofilms. Small. 2021;2100531:1\u201317. https:\/\/doi.org\/10.1002\/smll.202100531.","journal-title":"Small"},{"key":"1662_CR23","doi-asserted-by":"publisher","unstructured":"N. Lall, C. J. Henley-smith, M. N. De Canha, C. B. Oosthuizen, and D. Berrington, \u201cViability Reagent, PrestoBlue, in Comparison with Other Available Reagents , Utilized in Cytotoxicity and Antimicrobial Assays,\u201d Int J Microbiol., vol. 420601, 2013, doi: https:\/\/doi.org\/10.1155\/2013\/420601.","DOI":"10.1155\/2013\/420601"},{"issue":"1","key":"1662_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1021\/acsinfecdis.1c00444","volume":"8","author":"JC Horstmann","year":"2022","unstructured":"Horstmann JC, Laric A, Boese A, Yildiz D, R\u00f6hrig T, Empting M, Frank N, Krug D, M\u00fcller R, Schneider-Daum N, de Souza Carvalho-Wodarz C, Lehr CM. Transferring microclusters of P. Aeruginosa biofilms to the air-liquid Interface of bronchial epithelial cells for repeated deposition of aerosolized tobramycin. ACS Infect Dis. 2022;8(1):137\u201349. https:\/\/doi.org\/10.1021\/acsinfecdis.1c00444.","journal-title":"ACS Infect Dis"},{"issue":"4","key":"1662_CR25","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1128\/IAI.01373-07","volume":"76","author":"GG Anderson","year":"2008","unstructured":"Anderson GG, Moreau-Marquis S, Stanton BA, O\u2019Toole GA. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect Immun. 2008;76(4):1423\u201333. https:\/\/doi.org\/10.1128\/IAI.01373-07.","journal-title":"Infect Immun"},{"issue":"1\u20132","key":"1662_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0022-1759(00)00279-9","volume":"245","author":"LE DeForge","year":"2000","unstructured":"DeForge LE, Billeci KL, Kramer SM. Effect of IFN-\u03b3 on the killing of S. Aureus in human whole blood: assessment of bacterial viability by CFU determination and by a new method using alamarBlue. J Immunol Methods. 2000;245(1\u20132):79\u201389. https:\/\/doi.org\/10.1016\/S0022-1759(00)00279-9.","journal-title":"J Immunol Methods"},{"issue":"6","key":"1662_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1101\/pdb.prot095497","volume":"2018","author":"P Kumar","year":"2018","unstructured":"Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the lactate dehydrogenase assay. Cold Spring Harb Protoc. 2018;2018(6):465\u20138. https:\/\/doi.org\/10.1101\/pdb.prot095497.","journal-title":"Cold Spring Harb Protoc"},{"issue":"1","key":"1662_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ajps.2018.08.008","volume":"14","author":"J Cao","year":"2019","unstructured":"Cao J, et al. Development of PLGA micro- and nanorods with high capacity of surface ligand conjugation for enhanced targeted delivery. Asian J Pharm Sci. 2019;14(1):86\u201394. https:\/\/doi.org\/10.1016\/j.ajps.2018.08.008.","journal-title":"Asian J Pharm Sci"},{"key":"1662_CR29","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.2147\/IJN.S92271","volume":"11","author":"W Ji","year":"2016","unstructured":"Ji W, Lu S. A novel paclitaxel-loaded poly (D, L -lactide- co - glycolide) -tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment. Int J Nanomedicine. 2016;11:2119\u201331. https:\/\/doi.org\/10.2147\/IJN.S92271.","journal-title":"Int J Nanomedicine"},{"key":"1662_CR30","doi-asserted-by":"publisher","DOI":"10.5772\/15261","volume-title":"Soybean-based surfactants and their applications","author":"Q Xu","year":"2011","unstructured":"Xu Q, Nakajima M, Liu Z, Shiina T. Soybean-based surfactants and their applications. InTech; 2011. https:\/\/doi.org\/10.5772\/15261."},{"key":"1662_CR31","doi-asserted-by":"publisher","unstructured":"Bianchi F, et al. TLR3 expression induces apoptosis in human non-small-cell lung cancer. Int J Mol Sci. 2020;21(4) https:\/\/doi.org\/10.3390\/ijms21041440.","DOI":"10.3390\/ijms21041440"},{"issue":"1\u20133","key":"1662_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0168-3659(02)00356-5","volume":"87","author":"BI Florea","year":"2003","unstructured":"Florea BI, Cassara ML, Junginger HE, Borchard G. Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J Control Release. 2003;87(1\u20133):131\u20138. https:\/\/doi.org\/10.1016\/S0168-3659(02)00356-5.","journal-title":"J Control Release"},{"issue":"1\u20132","key":"1662_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijpharm.2007.05.023.Preparation","volume":"343","author":"JS Ashwin Basarkara","year":"2018","unstructured":"Ashwin Basarkara JS, Devinenib D, Palaniappanb R. Preparation, characterization, cytotoxicity and transfection efficiency of poly (DL-lactide-co-glycolide) and poly (DL-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA. HHS Public Access. 2018;343(1\u20132):247\u201354. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.05.023.Preparation.","journal-title":"HHS Public Access"},{"key":"1662_CR34","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.2147\/ijn.s24552","volume":"6","author":"S Mura","year":"2011","unstructured":"Mura S, et al. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomedicine. 2011;6:2591\u2013605. https:\/\/doi.org\/10.2147\/ijn.s24552.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"1662_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-13320-4","volume":"7","author":"JU Menon","year":"2017","unstructured":"Menon JU, et al. Dual-drug containing Core-Shell nanoparticles for lung Cancer therapy. Sci Rep. 2017;7(1):1\u201313. https:\/\/doi.org\/10.1038\/s41598-017-13320-4.","journal-title":"Sci Rep"},{"issue":"10","key":"1662_CR36","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1166\/jbn.2014.1939","volume":"10","author":"E Fattal","year":"2014","unstructured":"Fattal E, Grabowski N, Mura S, Vergnaud J, Tsapis N, Hillaireau H. Lung toxicity of biodegradable nanoparticles. J Biomed Nanotechnol. 2014;10(10):2852\u201364. https:\/\/doi.org\/10.1166\/jbn.2014.1939.","journal-title":"J Biomed Nanotechnol"},{"issue":"2","key":"1662_CR37","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.ijpharm.2013.05.025","volume":"454","author":"N Grabowski","year":"2013","unstructured":"Grabowski N, Hillaireau H, Vergnaud J, Arag\u00e3o L. Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells. Int J Pharm. 2013;454(2):686\u201394. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.05.025.","journal-title":"Int J Pharm"},{"key":"1662_CR38","unstructured":"Copley Scientific Limited, 2021. Driving results in inhaler testing. Driv Results Inhaler Test. 2021:1\u2013163. https:\/\/issuu.com\/pyramidpress\/docs\/inhaler_brochure_2020_vfinal_with_c_15cb536025b6f8\/1"},{"issue":"6","key":"1662_CR39","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.nano.2011.04.004","volume":"7","author":"AB Etame","year":"2011","unstructured":"Etame AB, Smith CA, Chan WCW, Rutka JT. Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomed Nanotechnol Biol Med. 2011;7(6):992\u20131000. https:\/\/doi.org\/10.1016\/j.nano.2011.04.004.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"1","key":"1662_CR40","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1021\/la4029035","volume":"30","author":"EA Mun","year":"2014","unstructured":"Mun EA, Hannell C, Rogers SE, Hole P, Williams AC, Khutoryanskiy VV. On the role of specific interactions in the diffusion of nanoparticles in aqueous polymer solutions. Langmuir. 2014;30(1):308\u201317. https:\/\/doi.org\/10.1021\/la4029035.","journal-title":"Langmuir"},{"issue":"1","key":"1662_CR41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ijpharm.2017.09.018.Physicochemical","volume":"532","author":"J Leal","year":"2018","unstructured":"Leal J, Smyth HDC, Ghosh D. Physicochemical properties of mucus and their impact on transmucosal drug delivery Jasmim. Int J Pharm. 2018;532(1):555\u201372. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.09.018.Physicochemical.","journal-title":"Int J Pharm"},{"issue":"11","key":"1662_CR42","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3390\/polym11111828","volume":"11","author":"Z Abid","year":"2019","unstructured":"Abid Z, Dalskov Mosgaard M, Manfroni G, Singh Petersen R, Hagner Nielsen L, M\u00fcllertz A, Boisen A, Sylvest Keller S. Investigation of Mucoadhesion and degradation of PCL and PLGA microcontainers for Oral drug delivery. Polymers (Basel). 2019;11(11):1828. https:\/\/doi.org\/10.3390\/polym11111828.","journal-title":"Polymers (Basel)"},{"issue":"1","key":"1662_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.drudis.2021.09.005","volume":"27","author":"E Pasqua","year":"2022","unstructured":"Pasqua E, Hamblin N, Edwards C, Baker-glenn C, Hurley C. Developing inhaled drugs for respiratory diseases: a medicinal chemistry perspective. Drug Discov Today. 2022;27(1):134\u201350. https:\/\/doi.org\/10.1016\/j.drudis.2021.09.005.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1662_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.aca.2006.04.038","volume":"571","author":"MX Guo","year":"2006","unstructured":"Guo MX, Wrisley L, Maygoo E. Measurement of tobramycin by reversed-phase high-performance liquid chromatography with mass spectrometry detection. Anal Chim Acta. 2006;571(1):12\u20136. https:\/\/doi.org\/10.1016\/j.aca.2006.04.038.","journal-title":"Anal Chim Acta"},{"issue":"3","key":"1662_CR45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/pharmaceutics12030264","volume":"12","author":"M Lee","year":"2020","unstructured":"Lee M. Liposomes for enhanced bioavailability of water-insoluble drugs: in vivo evidence and recent approaches. Pharmaceutics. 2020;12(3):264. https:\/\/doi.org\/10.3390\/pharmaceutics12030264.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1662_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/pharmaceutics8020018","volume":"8","author":"Z Rukavina","year":"2016","unstructured":"Rukavina Z, Vani\u0107 \u017d. Current trends in development of liposomes for targeting bacterial biofilms. Pharmaceutics. 2016;8(2):18. https:\/\/doi.org\/10.3390\/pharmaceutics8020018.","journal-title":"Pharmaceutics"},{"issue":"4","key":"1662_CR47","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3390\/molecules27041372","volume":"27","author":"P Liu","year":"2022","unstructured":"Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system\u00a0: current status of approved products, regulatory environments, and future perspectives. Molecules. 2022;27(4):1372. https:\/\/doi.org\/10.3390\/molecules27041372.","journal-title":"Molecules"},{"issue":"6","key":"1662_CR48","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1179\/joc.2010.22.6.378","volume":"22","author":"IMT Strateva","year":"2010","unstructured":"Strateva IMT, Petrova G. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria. J Chemother. 2010;22(6):378\u201383. https:\/\/doi.org\/10.1179\/joc.2010.22.6.378.","journal-title":"J Chemother"},{"issue":"10","key":"1662_CR49","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1111\/1462-2920.12155.The","volume":"15","author":"BS Tseng","year":"2013","unstructured":"Tseng BS, Zhang W, Joe JJ, Harrison, Quach TP, Song JL, Penterman MR, Singh PK, Chopp DL, Packman AI, Parsek. The extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the penetration of tobramycin. Env Microbiol. 2013;15(10):2865\u201378. https:\/\/doi.org\/10.1111\/1462-2920.12155.The.","journal-title":"Env Microbiol"},{"issue":"11","key":"1662_CR50","first-page":"45","volume":"62","author":"I Rivolta","year":"2011","unstructured":"Rivolta I, et al. Cellular uptake of Coumarin-6 as a model drug loaded in solid lipid nanoparticles. J Physiol Pharmacol. 2011;62(11):45\u201353.","journal-title":"J Physiol Pharmacol"},{"key":"1662_CR51","doi-asserted-by":"publisher","unstructured":"Goers L, Freemont P, Polizzi KM. Co-culture systems and technologies: taking synthetic biology to the next level. J R Soc Interface. 2014;11(96) https:\/\/doi.org\/10.1098\/rsif.2014.0065.","DOI":"10.1098\/rsif.2014.0065"},{"issue":"1","key":"1662_CR52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/bit.27562","volume":"118","author":"P Xu","year":"2021","unstructured":"Xu P. Dynamics of microbial competition, commensalism, and cooperation and its implications for coculture and microbiome engineering. Biotechnol Bioeng. 2021;118(1):199\u2013209. https:\/\/doi.org\/10.1002\/bit.27562.","journal-title":"Biotechnol Bioeng"},{"key":"1662_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2020.00494","volume":"10","author":"S Van Den Bossche","year":"2020","unstructured":"Van Den Bossche S, Vandeplassche E, Ostyn L, Coenye T, Crabb\u00e9 A. Bacterial interference with lactate dehydrogenase assay leads to an underestimation of cytotoxicity. Front Cell Infect Microbiol. 2020;10:1\u201311. https:\/\/doi.org\/10.3389\/fcimb.2020.00494.","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01662-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01662-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01662-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:13:33Z","timestamp":1740766413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01662-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1662"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01662-2","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"27 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable since study did not include animals or humans.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable since study did not include humans.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}